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SUCCESSFUL ELIMINATION OF FACTOR VIII INHIBITOR USING CYCLOSPORIN A
Acquired Factor VIII (FVIII) deficiency is an uncommon but
sometimes catastrophic autoimmune condition for which
standard immune suppression, such as steroid or immuno-
globulin infusion, is often insufficient to induce long-term
remission (Dykes et al, 2001). A number of second-line
therapies, such as cyclophosphamide, azathioprine and
vincristine, have been used with varying success (Morrison
& Ludlam, 1995). Here, we describe the use of cyclosporin A
in a patient in whom conventional treatments failed to
eradicate the inhibitor. At present, only limited experience
exists of its use in this setting (Pfliegler et al, 1989).
A 68-year-old woman with a 4-month history of easy
bruising presented with life-threatening retropharyngeal
haemorrhage. She had no significant past medical history,
and medication consisted of aspirin and naproxen. Coagu-
lation studies at presentation demonstrated a normal
prothrombin time and fibrinogen activity but a prolonged
activated partial thromboplastin time of 65 s (normal range
32–48 s). Factor assays confirmed a reduced FVIII coagu-
lant activity (FVIII:C) at 1 il ⁄ dl. An inhibitor was detected
and quantified at 54 Bethesda units (BU). von Willebrand
factor activity and antigen were both within the normal
range excluding acquired von Willebrand’s disease.
Her initial treatment was with high-purity plasma-
derived FVIII (Liberate, Scottish National Blood Transfusion
Service), commencing at 20 000 units twice daily, with
prednisolone 60 mg and high-dose intravenous immuno-
globulin (2 g ⁄ kg). Clinical response to treatment was
excellent with no further haemorrhage. The patient’s
inhibitor titre remained detectable at 10–20 BU with
FVIII:C remaining below 20 il ⁄ dl over the succeeding
months. The introduction of cyclophosphamide 50 mg
daily, 9 months after presentation, initially in conjunction
with further prednisolone (1 mg ⁄ kg), rendered the inhibitor
transiently undetectable, with FVIII:C peaking at 40 il ⁄ dl.
However, with reduction of the prednisolone dose, the
inhibitor returned, and the FVIII:C fell. After 9 months of
treatment with cyclophosphamide, it was discontinued
because of lack of a sustained response.
Approximately 28 months after presentation, cyclosporin
A (CyA) was introduced at 100 mg twice daily
(3 mg ⁄ kg ⁄ d), initially with prednisolone (1 mg ⁄ kg). A
target trough plasma CyA concentration of 200–250 mg ⁄ l
was achieved over 3 months with a dose of 175 mg twice
daily ( 5 mg ⁄ kg ⁄ d), during which time the prednisolone
was discontinued. The inhibitor titre fell and was undetect-
able 3 months after the commencement of CyA. The FVIII:C
rose to within the normal range following disappearance of
the inhibitor (Fig 1). After 14 months of therapy with CyA,
and with FVIII:C levels remaining in the normal range,
cyclosporine was reduced and stopped over a 4-month
period. Ten months after cessation of all immunosuppres-
sive therapy, the FVIII:C remains in the normal range with
no detectable inhibitor.
Permanent eradication of inhibitor without the need for
continued therapy is the ultimate aim of immunosuppres-
sive treatment for acquired haemophilia. Initial reduction in
inhibitor titre may be achieved with high-dose intravenous
immunoglobulin and steroids; however, long-term clear-
ance may not be achieved with this approach alone (Hay
et al, 1996). Further options include cytotoxic regimens or
immunosuppressant agents such as cyclosporine. As no
Fig 1. Factor VIII and inhibitor levels.
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regime has been universally successful, and there have been
no large immunomodulatory studies, no gold standard
treatment has been established (Grunewald et al, 2001).
Cytotoxic therapy may be associated with neutropenic
sepsis; such cases have been reported in the treatment of
acquired haemophilia (Lian et al, 1989). On the other hand
CyA is well recognized as a precipitant of hypertension and
renal impairment in addition to its anticipated immuno-
suppressive effects. The choice of treatment must then rest
on the perceived risk of the options available.
This case demonstrates a lasting response attributed to
CyA that was not achieved either by first-line therapy with
steroid and intravenous immunoglobulin or by second-line
therapy with cyclophosphamide. Although we cannot
exclude spontaneous remission of the patient’s FVIII inhib-
itor, the reduction in inhibitor titre commensurate with the
introduction of CyA makes this unlikely. We conclude that
CyA warrants consideration in patients refractory to first-
line therapy for this rare but serious autoimmune disorder.
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MISCONCEPTIONS IN THALASSAEMIA DIAGNOSIS
A full blood count was requested on a 2-day-old Pakistani
boy. The child had mild anaemia with thalassaemic indices,
blood film showed anisocytosis, poikilocytosis, target cells
and polychromasia (Table I). High-performance liquid chro-
matography suggested a three alpha gene deletion with
haemoglobin Barts 27Æ7%, haemoglobin F 44Æ6% and hae-
moglobin A 19%.
The mother’s prenatal test results were normal (Table I).
The father’s results suggested alpha-thalassaemia trait or
silent beta-thalassaemia trait (Table I). No other antenatal
testing had been done as the fetus was not felt to be at risk of
serious haemoglobinopathy.
Further questioning of the mother revealed she had had
in vitro fertilization (IVF) using donated ova in another UK
city. The donor, from Cyprus, had declared a family history
of thalassaemia at the IVF clinic and therefore underwent
screening. This was reported as showing possible iron
deficiency, and a card was issued stating that she had no
significant haemoglobinopathy. Antenatal haemoglobinop-
athy screening for the biological mother during a previous
pregnancy had also been reported as normal. Two further
separate screens over a period of years had failed to
comment on the significance of thalassaemic indices in
the presence of a normal haemoglobin and Hb A2.
DNA analysis showed the natural mother to have a
Mediterranean a0 deletion (–MED ⁄aa), the father a 3Æ7-kb
a+-thalassaemia deletion (–a3Æ7 ⁄ aa) and the baby haemo-
globin H disease (–a3Æ7 ⁄ –MED).
The donated ova from the same woman had also been
used in other pregnancies, including a pregnancy using the
donated ova and a sperm donor of Asian origin. This sperm
donor had not had a haemoglobinopathy screen and had to
be recalled.
This case highlights common problems in thalassaemia
diagnosis, screening and reporting. Although guidelines for
the laboratory diagnosis of haemoglobinopathies exist
(British Committee for Standards in Haematology, General
Haematology, 1998), there is currently no standardized
reporting of results. The British Committee for Standards in
Haematology (BCSH) guidelines state that screening is
equally important in cases where pregnancy is the result of
artificial insemination from a donor or in vitro fertilization,
Table I. Haematology results of the patient and his parents.
Hb
(g ⁄ dl)
MCV
(fl)
MCH
(pg)
RBC
(· 1012 ⁄ l)
HbA2
(%)
HbF
(%)
Sickle
test
Baby 10Æ8 75 22Æ9 6Æ03
Father 14Æ3 81Æ5 26Æ9 5Æ31 2Æ2 < 1Æ0 Negative
Mother 13Æ1 82Æ5 28Æ3 4Æ64 2Æ5 < 1Æ0 Negative
Donor 13Æ2 66 20Æ5 6Æ44 2Æ9 < 1Æ0 Negative
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yet confidentiality issues mean that this information does
not have to be passed on. Screening of both egg and semen
donors is also recommended by the Human Fertilization and
Embryology Authority, 2001), the British Andrology Soci-
ety, 199) and the British Fertility Society (2000).
Although the majority of populations at risk of a-thalas-
saemia have a+ deletions, it is recommended that the
a0-thalassaemia trait should be detected in prospective
parents to predict the occurrence of haemoglobin Barts
hydrops fetalis.
Mutations causing the a0-thalassaemia trait are found
predominantly in south-east Asia, southern China (–SEA ⁄aa,
–FIL ⁄aa and –THAI ⁄ aa) and the Mediterranean, particularly
Cyprus, Turkey and Greece (–MED ⁄ aa).
DNA analysis should be done in patients from these
ethnic groups with a MCH < 25 pg and where b- and
db-thalassaemia and haemoglobin Lepore have been
excluded.
In this case, the ethnic origin of the natural mother was
not taken into account and the a0-thalassaemia trait
therefore not considered. In such cases, it is necessary to
add a statement that the ‘a-thalassaemia trait cannot be
excluded’ whether iron deficiency is present or not.
The National Health Service (NHS) plan is committed to a
national, linked antenatal and neonatal screening pro-
gramme for the haemoglobinopathies (NHS Plan, 2000).
We anticipate that this will give clear guidance as to which
population groups are to be screened to achieve standard-
ized reporting. These guidelines should include advice
regarding the screening of semen and egg donors.
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